A Pharmacodynamic Study of Measured Glomerular Filtration Rate in Patients With Chronic Kidney Disease and Type 2 Diabetes

Summary

This is a 24-week multi-center, double-blind, randomized, exploratory study of bardoxolone methyl treatment in 18 patients with Stage 3 CKD (eGFR greater than or equal to 30.0 to less than 60.0 ml/min/1.73m2) and diabetes to ensure at least 15 patients complete the study for evaluation of the primary endpoints.

Timeline

Start

2012-01-31

Primary completion

2012-11-01

Completion

2013-10-01

Outcome

Outcome not reported

Stopped: “IDMC recommendation for safety concerns”

Drugs

Indications